Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions
 
Status Suspended
Process STA
Referral date 01 May 2011
Topic area
  • Cardiovascular
Description

Scoped within Batch 17

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: Bijal Joshi
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
8 June 2012 The Institute has now been informed by the manufacturer that it is not currently pursuing a licensing application for rivaroxaban in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
25 August 2011

As you are aware, the Department of Health has asked us to carry out a single technology appraisal of rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions.

Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.

The deadline for evidence submission, which was 3 October 2011, no longer applies in this instance.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance